Skip to content
Screener

Arrowhead Research ARWR Total Liabilities & Equity

Total Liabilities & Equity at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$2.99B+0.3%
ALN
Alnylam PharmaceuticalsALNY
$5.56B+21.7%
Assembly Biosciences logo
Assembly BiosciencesASMB
$235.51M+138%
Arbutus Biopharma Corporation logo
Arbutus Biopharma CorporationABUS
$277.16M+137%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$1.26B-3.2%
Beam Therapeutics logo
Beam TherapeuticsBEAM
$1.48B+0.9%

Other financials

Income statement

See full
Revenue$73.7M-86.4%
Operating income-$141.3M-137%
Net income-$132.7M-136%
EPS (diluted)-$0.93-134%

Balance sheet

See full
Cash & equivalents$188.5M+1.5%
Total debt$107.9M-5.6%
Total equity$614.0M-10.1%
Total assets$2.3B+44.2%

Cash flow

See full
Operating cash flow$84.4M-81.6%
CapEx$2.6M-51.6%
Free cash flow$81.9M-82.0%

Valuation

See full
Market cap$12.28B+445%
Enterprise value$12.2B+446%
P/S19.7×+15.8×

Profitability

See full
Operating margin-35.7%+63.6pp
Net margin-48.4%+240pp
FCF margin1.8%+0.9pp

Returns & leverage

See full
Return on equity-46.4%+341pp
Debt / equity0.2×0.0×
Current ratio6.2×+1.1×

Where this comes from

Reported directly by Arrowhead Research in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.

The source filing: Arrowhead Research’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:05 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q1 2026
Accession
0000879407-26-000047
Line itemMarch 31, 2026September 30, 2025
Additional paid-in capital2,395,2672,139,725
Accumulated other comprehensive income7426,443
Accumulated deficit(1,729,075)(1,627,154)
Treasury stock; at cost; 2,661 shares of common stock at March 31, 2026 and September 30, 2025(53,193)(53,193)
Stockholders’ equity613,977466,052
Noncontrolling interest(15,061)37,364
Total noncontrolling interest and stockholders’ equity598,916503,416
Total Liabilities, Noncontrolling Interest and Stockholders’ Equity$2,268,265$1,385,295

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Arrowhead Research's total liabilities & equity?
Arrowhead Research (ARWR) reported total liabilities & equity of $2.27B in Q1 2026.
How has Arrowhead Research's total liabilities & equity changed year-over-year?
Arrowhead Research's total liabilities & equity increased by 44.2% year-over-year, from $1.57B to $2.27B.
What is the long-term trend for Arrowhead Research's total liabilities & equity?
Over 4 years (2021 to 2025), Arrowhead Research's total liabilities & equity has grown at a 18.2% compound annual growth rate (CAGR), from $710.15M to $1.39B.
What does total liabilities & equity mean?
Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.

Ask your AI about Arrowhead Research's total liabilities & equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude